


AMENDMENTS TO THE CLAIMS

1. - 7. (Canceled)

8. (Currently Amended) A method for expressing long-term potentiation of synaptic transmission, comprising administering to a patient in need thereof an effective amount of a compound



wherein

R⁴ is lower alkanoyl,

R⁷ is phenyl substituted with halogen,

Z is a single bond,

J is -NH-, and

Q is -CO-,

or pharmaceutically acceptable salts thereof.

9. - 12. (Canceled)

13. (Previously Presented) The method for expressing long-term potentiation of synaptic transmission of claim 8, which is a method for the prophylaxis or treatment of one or more cerebral diseases.

14. (Previously Presented) The method for expressing long-term potentiation of synaptic transmission of claim 13, wherein said cerebral disease is dementia or amnesia.

15. - 30. (Canceled)

→ 31. (Currently Amended) A method for screening an agent for expression of long-term potentiation of synaptic transmission, which comprises stimulating hippocampal slices,


112 enablement

in vitro comp

Handwritten notes on the right side of the page:

- in vitro
- late with double
- transporter
- in vitro comp
- OK
- merch is what you have to get
- prevent

bringing a hippocampal slice into contact with a test compound having the following formula:



wherein

R⁴ is lower alkanoyl,

R⁷ is phenyl substituted with halogen,

Z is a single bond,

J is -NH-, and

Q is -CO-,

or pharmaceutically acceptable salts thereof,

measuring an amount of somatostatin released from the hippocampal slice and/or a release time thereof, measuring an amount of somatostatin released from a hippocampal slice and/or a release time thereof in the absence of a contact with the test compound, and comparing the amounts and/or the times to calculate the amount of somatostatin released from the hippocampal slice and/or the release time thereof caused by the contact with the test compound.

→ 32. (Original) The screening method according to claim 31, which is a screening method of an anti-dementia agent or anti-amnesia agent. ⇒ in vivo

33. (Canceled)

34. (Previously Presented) A method for expressing long-term potentiation of synaptic transmission, comprising administering to a patient in need thereof an effective amount of a compound obtained by the screening method of claim 31.

35. (Canceled)

36. (Previously Presented) A pharmaceutical composition for expression of long-term potentiation of synaptic transmission which comprises a compound obtained by the screening method of claim 31 and a pharmaceutically acceptable carrier or excipient.

37. (Canceled)

38. (Previously Presented) A compound selected by the screening method of claim 31.

39. – 55. (Canceled)

56. (Previously Presented) The method of claim 8, wherein said compound is N-(1-acetylpiperidin-4-yl)-4-fluorobenzamide.